Welcome to the ninth issue of the Neuronet newsletter!
We hope this newsletter finds you well. As we look back at 2021, we’re proud to provide you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration (ND).
Beginning this year with great news, we're happy to announce that our project has received from IMI an extension of 6 months until the end of August 2022.
We were pleased to see that our third Neuronet networking event, as part of the Alzheimer Europe conference from 29 November to 1 December, was a great success. New this year was a session on the gap between preclinical and clinical research and another reporting on the NEURONET Working Groups on data sharing, ethics and privacy, regulatory interactions and sustainability. We would like to thank all chairs, presenters and participants!
Having the general public in mind, our communications team has, as always, conducted interviews with early-careers researchers, showcasing their work in IMI ND projects. This issue features authors of relevant recent publications: Anna Mallach (PHAGO), Hannah Scheiblich (PD-MitoQUANT), as well as Alison Keogh (Mobilise-D).
Furthermore, we're excited to announce that the IMI neurodegeneration programme has grown further, with the new EPND project joining our community! The goal of EPND is to become a future European infrastructure, facilitating access to biological samples and data to accelerate biomarker discovery and validation, and eventually support the development of therapeutics for neurodegenerative diseases.
Last but not least, we would like to highlight that IMI’s successor, Europe’s new partnership for health - the “Innovative Health Initiative” - will hold a launch event on 26th January!
Happy reading and enjoy!
CEO, SYNAPSE Research
Neuronet Project Leader
Clinical Scientist, Janssen